Method for treating heart disease by inhibiting the Coxsackievirus-Adenovirus Receptor
The invention pertains to a means for downregulating or inhibiting or mislocalizing CAR in a cardiac cell for treating/curing a patient who has suffered or is predisposed to suffering a myocardial infarction (MI) or preventing myocardial infarction or complications thereof.
1. A method for down-regulating or inhibiting Coxsackievirus-Adenovirus Receptor (CAR) in a heart of a subject not suffering from myocarditis, comprising administering to the subject at least one of:
a CAR protein ligand or a CAR protein ligand fragment, wherein the heart is a heart subjected to inadequate perfusion.
2. The method of claim 1 , wherein the down-regulating or inhibiting Coxsackievirus-Adenovirus Receptor (CAR) in the heart of a subject comprises administering to the subject at least one of an antibody specifically binding to the CAR, a specifically binding fragment of the antibody, a CAR-Fc-fusion protein, fibronectin, a CAR ligand fusion protein and a fusion protein of any of the before-mentioned proteins.
3. A method for down-regulating or inhibiting Coxsackievirus-Adenovirus Receptor (CAR) in a cardiac cell of a subject not suffering from myocarditis, comprising:
functionally inhibiting a CAR protein by administering to the subject a CAR protein ligand, wherein the cardiac cell is a cardiac cell subjected to inadequate perfusion.
4. The method of claim 3 , wherein the functional inhibition of the CAR protein is achieved using at least one of an antibody specifically binding to the CAR, a specifically binding fragment of the antibody, a CAR-Fc-fusion protein, and fibronectin.
5. A method for down-regulating or inhibiting Coxsackievirus-Adenovirus Receptor (CAR) in a heart of a subject not suffering from myocarditis, comprising administering to the subject at least one of:
a CAR protein ligand or a CAR protein ligand fragment, wherein the heart is a heart subjected to ischemia.